Views & Analysis The best-selling drugs of the next 5 years Merck & Co’s immuno-oncology drug Keytruda (pembrolizumab) is projected to be the best-selling dru
News Merck claims a brace of head and neck cancer approvals Merck & Co/MSD has done the double in head and neck cancer with a pair of FDA approvals for Keytruda in newly diagnosed patients on the same day.
News Repligen builds in cell therapy with $1.5bn BioLife takeover Repligen has reached a deal to buy cell therapy specialist BioLife Solutions for $1.5bn, tapping into a market growing at breakneck speed.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
